CAS, a division of the American Chemical Society specializing in scientific information solutions, has announced several initiatives to once again transform scientific research, and empower more rapid discovery for life sciences innovation.
CAS is expanding its comprehensive, highly structured, human-curated scientific data with the introduction of life sciences assets. The CAS Content Collection™ now includes exhaustive biological sequences and bioactivity information designed to accelerate early-stage drug discovery research, with future additions including antibodies, omics, and more.
CAS is collaborating with Chemotargets to leverage Clarity® to serve as its technology foundation for rapid development, with future investments driving integration and expansion to cover the end-to-end pharmaceutical R&D workflow and accelerate therapeutic innovation.
CAS recently established a Life Sciences Industry Advisory Board comprising a world-class panel of global thought leaders from commercial, academic, and government organizations. Under their advisement, CAS life sciences investments will continue, with focused content and capabilities to drive better decisions early in the drug discovery process from understanding disease progression with its comprehensive biological pathway data to assessing the effectiveness of investigational drugs with enriched molecular biomarker data.
Click here to read the original press release.
